Kevin D Scanlon

US Patent:

20020055470, May 9, 2002

Filed:

Jun 26, 2001

Appl. No.:

09/891229

Inventors:

Kevin Scanlon - Pasadena CA, US
Lawrence Sowers - Duarte CA, US

Assignee:

CITY OF HOPE - Duarte CA

International Classification:

A61K031/7076
A61K031/52
A61K038/00

US Classification:

514/021000, 514/045000, 514/261000

Abstract:

A method involving the administration of nucleoside analogs to circumvent resistance attributable to the enhanced DNA repair capacity of cancer cells is described. The nucleoside analogs function as suicide substrates for DNA repair enzymes. A method of screening nucleoside analogs for utility as antitumor agents and a screening assay to individual recurrent tumors is described.

US Patent:

55853633, Dec 17, 1996

Filed:

Feb 28, 1995

Appl. No.:

8/396068

Inventors:

Kevin J. Scanlon - Pasadena CA
Lawrence C. Sowers - Duarte CA

Assignee:

City of Hope - Duarte CA

International Classification:

A61K 3170
A61K 31395
A61K 9127

US Classification:

514 45

Abstract:

A method involving the administration of nucleoside analogs to circumvent resistance attributable to the enhanced DNA repair capacity of cancer cells is described. The nucleoside analogs function as suicide substrates for DNA repair enzymes. A method of screening nucleoside analogs for utility as antitumor agents and a screening assay to individual recurrent tumors is described.

US Patent:

51661403, Nov 24, 1992

Filed:

Oct 13, 1989

Appl. No.:

7/421342

Inventors:

Kevin J. Scanlon - Pasadena CA
Lawrence C. Sowers - Duarte CA

Assignee:

City of Hope - Duarte CA

International Classification:

A61K 3170
A61K 3152
A61K 31505

US Classification:

514 45

Abstract:

A method involving the administration of nucleoside analogs to circumvent resistance attributable to the enhanced DNA repair capacity of cancer cells is described. The nucleoside analogs function as suicide substrates for DNA repair enzymes. A method of screening nucleoside analogs for utility as antitumor agents and a screening assay to individual recurrent tumors is described.

US Patent:

50859838, Feb 4, 1992

Filed:

May 17, 1989

Appl. No.:

7/352994

Inventors:

Kevin J. Scanlon - Pasadena CA

Assignee:

City of Hope - Duarte CA

International Classification:

C12Q 168
C12P 1934
G01N 33566
C07H 1512

US Classification:

435 6

Abstract:

Changes in tumor cell RNA and DNA are utilized to detect the progression and the temporal changes in resistance to chemotherapy in human tumors.

US Patent:

58144897, Sep 29, 1998

Filed:

Aug 4, 1995

Appl. No.:

8/511237

Inventors:

Kevin J. Scanlon - Pasadena CA

Assignee:

City of Hope - Duarte CA

International Classification:

C12P 1934

US Classification:

435 912

Abstract:

A method for producing a contaminating DNA free single stranded PCR amplification product of mRNA is disclosed. The mRNA amplification product is of lower molecular weight and is readily separated, e. g. , by gel electrophoresis, from any amplified cellular DNA contaminant.

US Patent:

59899085, Nov 23, 1999

Filed:

May 23, 1997

Appl. No.:

8/793878

Inventors:

Kevin J. Scanlon - Pasadena CA

Assignee:

City of Hope - Duarte CA

International Classification:

C12N 1585
C07H 2104
C12Q 168

US Classification:

435325

Abstract:

The effects of suppressing c-fos oncogene expression on drug or radiation resistant mammalian cells are described. A2780S human ovarian carcinoma cells with resistance to actinomycin D were isolated and the resultant A2780AD cells exhibited the MDR phenotype. A hammerhead ribozyme designed to cleave fos RNA cloned into the pMAMneo plasmid was transfected into A2780AD cells. Induction of the ribozyme resulted in decreased expression of c-fos, followed by that of mdr-1, c-jun, and p53. Reversal of the MDR phenotype by the anti-mdr ribozyme occurred one-fourth as rapidly as that induced by the anti-fos ribozyme. These studies demonstrate the primacy of the c-fos oncogene in maintaining the resistant phenotype in human cancer cells. Thus, down regulation of fos/jun will make resistant cancer cells more sensitive to conventional treatment, i. e. , cancer chemotherapeutic agents and/or radiation.

US Patent:

57363269, Apr 7, 1998

Filed:

Aug 31, 1994

Appl. No.:

8/299332

Inventors:

Kevin J. Scanlon - Pasadena CA

Assignee:

City of Hope - Duarte CA

International Classification:

C12P 1934
C12Q 168

US Classification:

435 6

Abstract:

This invention provides a process for detecting acquired resistance to any chemotherapeutic agent by any type of human cancer cell. The process comprises assaying RNA from human cancer cells to determine whether the expression of at least one of a preselected spectrum of least two different genes is increased in comparison to a control.

US Patent:

58802770, Mar 9, 1999

Filed:

Jul 16, 1997

Appl. No.:

8/895235

Inventors:

Kevin J. Scanlon - Pasadena CA

Assignee:

City of Hope - Duarte CA
The Regents of the University of California - Oakland CA

International Classification:

C07H 2104

US Classification:

536 245

Abstract:

The steroid enzyme 5. alpha. -reductase is responsible for the conversion of testosterone to the more-potent androgen dihydrotestosterone (DHT). The catalytic cleavage of nucleic acid encoding 5. alpha. -reductase by a ribozyme which selectively recognizes such nucleic acid reduces the level of expression of 5. alpha. -reductase by mammalian cells including human cells treated with such ribozyme. The reduction of nucleic acid (e. g. mRNA) levels leads to a corresponding reduction of enzyme levels and dihydrotestosterone levels in surrounding tissues, thus providing a therapeutic effect. The transformation of 5. alpha. -reductase producing cells with an expression vector containing a structural gene for a ribozyme is shown to decrease 5. alpha. -reductase expression. Pharmaceutical compositions and methods useful for topically administering effective amounts of such a ribozyme to hair follicle cells also are exemplified.